Galcanezumab was found to be beneficial in patients with treatment-resistant migraine, according to results from the phase 3 CONQUER study.
All articles by Diana Ernst, RPh
While no adverse events have been reported to date, the use of this product could potentially cause serious adverse reactions.
The FDA is looking to make the information in the Drug Abuse and Dependence section of product labeling more consistent and clear through a new draft guidance.
The use of cannabidiol (CBD), the non-intoxicating component of cannabis, has been associated with numerous adverse effects based on available evidence from animal and human studies.
Compared with other short acting opioids, patients prescribed tramadol may be at greater risk of prolonged use following surgery, according to a study published in The BMJ.
A recall of 1 lot of Ketorolac Tromethamine Injection 60mg/2mL (30mg/mL) has been initiated by Sagent Pharmaceuticals following the discovery of microbial growth during a routine simulation of the manufacturing process. Concerns over the possible introduction of microorganisms into the product led the Company to issue the recall to the user level. The product is…
Teva announced that the ENFORCE phase 3 program for fremanezumab in the treatment of cluster headaches will be discontinued following results from a futility analysis.
The FDA has accepted for review the Biologics License Application for eptinezumab (Alder BioPharmaceuticals), an investigational CGRP inhibitor for migraine prevention.
Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38% has been made available by Bausch + Lomb for the treatment of postoperative inflammation and pain following ocular surgery.
The Food and Drug Administration has announced that the Risk Evaluation and Mitigation Strategy (REMS) for transmucosal immediate-release fentanyl (TIRF) medications has been updated to better ensure the safe use of these products.